Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Generic drugFirst approved 1982

Orphenadrine Citrate

Medicare prescription drug cost, prescriptions and prescribers, 2024

$236K

Medicare cost, 2024

Medicare drug plans spent $235,935 on Orphenadrine Citrate in 2024, for 4,520 prescriptions and refills filled by 3,215 patients. Spending fell 56% from 2023 to 2024. Puerto Rico accounts for the most spending ($205,516, 87% of the total).

Medicare cost, 2024

$236K

-55.6% from 2023

Prescriptions

4,520

$52.20 per claim

Patients

3,215

1,288 prescribers

Total spending, 2024

$236K

$73.39 per patient

Questions and answers

How much does Medicare spend on Orphenadrine Citrate?

Medicare prescription drug plans paid $236K for Orphenadrine Citrate in 2024, for 4,520 prescriptions and refills to 3,215 patients (down 55.6% from 2023). The average cost per claim was $52.20.

Which state spends the most on Orphenadrine Citrate?

Puerto Rico had the highest Medicare cost for Orphenadrine Citrate in 2024: $206K for 4,267 claims, followed by Illinois ($8,806).

Who prescribes Orphenadrine Citrate the most?

Jan J Kraemer, interventional pain management in San Juan, PR, had the highest Medicare cost for Orphenadrine Citrate in 2024: 23 claims costing $8,728.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Orphenadrine Citrate was $236K in 2024, after a high of $747K in 2022.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Orphenadrine Citrate, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Jan J Kraemer San Juan, PRInterventional Pain Management2312$8,728
Rafael Soto Toa Baja, PRGeneral Practice23Under 11$7,087
Richard Graulau Rosario Cidra, PRGeneral Practice5821$7,012
Kurt R Bravata Buffalo, MOFamily Practice22Under 11$5,029
Roberto Ruiz-Lopez San Juan, PRInternal Medicine17Under 11$3,859
George J Urban Chicago, ILInternal Medicine24Under 11$3,339
Alfred R Johnson Richardson, TXInternal Medicine17Under 11$3,221
Angel Vazquez Urquia Corozal, PRGeneral Practice27Under 11$2,976
Maricarmen Quinones San Juan, PRGeneral Practice15Under 11$2,958
Maria C Cruz-Lartigaut Vega Alta, PRNeurology22Under 11$2,774
Edgar J Ramos Mendez Barceloneta, PRFamily Practice4026$2,463
Hector A Tirado Davila Sr. Bayamon, PRGeneral Practice4925$2,459
Carlos A Gil Barceloneta, PRGeneral Practice2918$2,204
Merle L Diamond Chicago, ILInternal Medicine15Under 11$1,669
Javier F Rios III Carolina, PRPhysical Medicine and Rehabilitation13Under 11$1,620
Luis A Paz Reyes Vega Baja, PRGeneral Practice20Under 11$1,616
Aurea T Negron Valcarcel Hato Rey, PRAnesthesiology14Under 11$1,579
Luis F Garcia-Jaunarena San Juan, PRRheumatology16Under 11$1,287
Ana G Beauchamp-Irizarry Ponce, PRInternal Medicine1611$1,286
Kate E Hesser Crete, NEFamily Practice25Under 11$1,213
Frank Campos Lopez Ciales, PRGeneral Practice15Under 11$1,147
Jorge L Torres-Martinez Salinas, PRGeneral Practice3426$1,126
Jose M Mendez Jiminian Fajardo, PRGeneral Practice19Under 11$1,111
Daylin Guerrero Caballero Lares, PRGeneral Practice14Under 11$1,015
Ana P Castro Corozal, PRInternal Medicine14Under 11$974

Prescriber data by year

YearPrescribersClaimsPatientsCost
20221,6887,5524,889$748K
20231,6917,7705,305$532K
20241,2884,5203,215$236K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
West-Ward/HikmaHIK.L logoHIK.L3,022$164K
Sagent Pharmace1,026$40K
Akorn Inc.382$24K
Hikma PharmaceuHIK.L logoHIK.L92$7,935

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
53
RxNorm concept IDs
994521, 994541
Application numbers
ANDA040284, ANDA040327, ANDA040463, ANDA084779, ANDA090585

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube